48 related articles for article (PubMed ID: 16080569)
1. Nuclear area is a prognostic determinant in advanced colorectal cancer.
Buhmeida A; Ristamäki R; Lamlum H; Bendardaf R; Heikkilä S; Collan Y; Syrjänen K; Pyrhönen S
Anticancer Res; 2005; 25(4):3083-8. PubMed ID: 16080569
[TBL] [Abstract][Full Text] [Related]
2. Nuclear size as prognostic determinant in stage II and stage III colorectal adenocarcinoma.
Buhmeida A; Algars A; Ristamäki R; Collan Y; Syrjänen K; Pyrhönen S
Anticancer Res; 2006; 26(1B):455-62. PubMed ID: 16739305
[TBL] [Abstract][Full Text] [Related]
3. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
4. Nuclear morphometry in prognostication of breast cancer in Saudi Arabian patients: comparison with European and African breast cancer.
Buhmeida A; Al-Maghrabi J; Merdad A; Al-Thubaity F; Chaudhary A; Gari M; Abuzenadah A; Collan Y; Syrjänen K; Al-Qahtani M
Anticancer Res; 2010 Jun; 30(6):2185-91. PubMed ID: 20651368
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
[TBL] [Abstract][Full Text] [Related]
6. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
Yi JH; Kim H; Jung M; Shin SJ; Choi JS; Choi GH; Baik SH; Min BS; Kim NK; Ahn JB
Oncology; 2013; 85(5):283-9. PubMed ID: 24217184
[TBL] [Abstract][Full Text] [Related]
8. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer.
Saunders MP; Hogg M; Carrington B; Sjursen AM; Allen J; Beech J; Swindell R; Valle JW
Br J Cancer; 2004 Oct; 91(8):1447-52. PubMed ID: 15452550
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
[TBL] [Abstract][Full Text] [Related]
11. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.
Gholam D; Giacchetti S; Brézault-Bonnet C; Bouchahda M; Hauteville D; Adam R; Ducot B; Ghémard O; Kustlinger F; Jasmin C; Lévi F
Oncologist; 2006; 11(10):1072-80. PubMed ID: 17110626
[TBL] [Abstract][Full Text] [Related]
12. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
Masi G; Vasile E; Loupakis F; Cupini S; Fornaro L; Baldi G; Salvatore L; Cremolini C; Stasi I; Brunetti I; Fabbri MA; Puglisi M; Trenta P; Granetto C; Chiara S; Fioretto L; Allegrini G; Crinò L; Andreuccetti M; Falcone A
J Natl Cancer Inst; 2011 Jan; 103(1):21-30. PubMed ID: 21123833
[TBL] [Abstract][Full Text] [Related]
14. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
Souglakos J; Pallis A; Kakolyris S; Mavroudis D; Androulakis N; Kouroussis C; Agelaki S; Xenidis N; Milaki G; Georgoulias V
Oncology; 2005; 69(5):384-90. PubMed ID: 16319509
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
Bamias A; Papamichael D; Syrigos K; Pavlidis N
J Chemother; 2003 Jun; 15(3):275-81. PubMed ID: 12868555
[TBL] [Abstract][Full Text] [Related]
16. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Meropol NJ; Gold PJ; Diasio RB; Andria M; Dhami M; Godfrey T; Kovatich AJ; Lund KA; Mitchell E; Schwarting R
J Clin Oncol; 2006 Sep; 24(25):4069-77. PubMed ID: 16943524
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
Fisher MD
Clin Colorectal Cancer; 2001 Aug; 1(2):85-6. PubMed ID: 12445365
[No Abstract] [Full Text] [Related]
18. Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy.
Ratanatharathorn V; Sirachainan E; Jirajarus M; Sirilerttrakul S
J Med Assoc Thai; 2000 Oct; 83(10):1187-95. PubMed ID: 11143484
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy with irinothecan, 5-fluorouracil and folinic acid in the first-line management of advanced colorectal carcinoma: retrospective study.
Man S; Lavrenkov K; Gluzman A; Geffen DB; Cohen Y
J Chemother; 2003 Jun; 15(3):304-5. PubMed ID: 12868563
[No Abstract] [Full Text] [Related]
20. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
